Sercan Avul

Sercan Avul

Auto-generated profile, based on publicly available information

Sercan Avul

Department of Internal Medicine, Kestel State Hospital, Bursa, Turkey

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 February 2025 in Turkish Journal of Gastroenterology
Verified
Journal Article
Open access
MKMURAT KESKİN
MURAT KESKİN
HAHanife Aysegul Arsoy
Hanife Aysegul Arsoy
OKOzlem Kara
Ozlem Kara
ESEmre Sarandöl
Emre Sarandöl
ABAylin Beyaz
Aylin Beyaz
Yusuf YilmazYusuf Yilmaz
Yusuf Yilmaz
Background/Aims: Metabolic dysfunction-associated steatotic liver disease (MASLD) in adolescents, including non-obese phenotypes, is an increasingly important public health issue. The current study investigated the use of controlled attenuation parameter (CAP) and liver stiffness measurement (LSM) as non-invasive tools, along with fibroblast growth factor-21 (FGF-21) and cytokeratin-18 (CK-18), in non-obese MASLD, obese MASLD, and healthy control groups, exploring metabolic and hepatic profiles in these groups. Materials and Methods: This cross-sectional study recruited 195 adolescents aged 9-18 years, stratified into controls (n = 92), non-obese MASLD (n = 32), and obese MASLD (n = 39) groups according to FibroScan and MASLD diagnostic criteria. FibroScan measured LSM and CAP, while enzyme-linked immunosorbent assay kit (ELISA) was used to analyze serum FGF-21 and CK-18 levels. Anthropometric, metabolic, and liver enzyme parameters were assessed. Results: Metabolic dysfunction-associated steatotic liver disease groups had higher LSM than controls. Fibroblast growth factor-21 levels were significantly higher in MASLD groups, especially in obese MASLD, while CK-18 levels showed variability without significant group differences. Obese MASLD adolescents had marked metabolic dysfunction with higher insulin, homeostasis model assessment for insulin resistance, triglycerides, and liver enzymes compared to non-obese MASLD and controls. Conclusion: Fibroblast growth factor-21 has emerged as a potential biomarker for assessing metabolic dysfunction in MASLD, while LSMs from FibroScan provide valuable insights into fibrosis risk. Elevated FGF-21 levels and FibroScan parameters reflect their potential usefulness in non-invasive assessment of MASLD severity, particularly in obese adolescents. However, further longitudinal studies are needed to establish their roles in predicting disease progression and guiding clinical management. Cite this article as: Keskin M, Aysegul Arsoy H, Kara O, et al. Metabolic and hepatic profiles of non-obese and obese metabolic dysfunction-associated steatotic liver disease in adolescents: the role of FibroScan parameters, fibroblast growth factor-21, and cytokeratin-18. Turk J Gastroenterol. 2025;36(3):152-161.

5 October 2026 in BMC Endocrine Disorders
Verified
Journal Article
Open access
PDF file
MUHAMMET FATİH Fatih ŞAHİNMUHAMMET FATİH Fatih ŞAHİN
MUHAMMET FATİH Fatih ŞAHİN
AŞAli Şahin
Ali Şahin
ADAyten Başak Karaakın Dinar
Ayten Başak Karaakın Dinar
SASercan Avul
Sercan Avul
SISümeyra Nur İzEet
Sümeyra Nur İzEet
ALİ EROLALİ EROL
ALİ EROL
To evaluate whether sodium-glucose cotransporter-2 (SGLT2) inhibitor use is associated with osteoporosis and dual-energy X-ray absorptiometry (DEXA)-derive

5 March 2024 in Heliyon
Verified
Journal Article
Open access
MKMURAT KESKİN
MURAT KESKİN
SASercan Avul
Sercan Avul
ABAylin Beyaz
Aylin Beyaz
Nizameddin KocaNizameddin Koca
Nizameddin Koca
This comprehensive study delves into the potential link between Neuromedin U (NmU) serum levels and the development of non-alcoholic fatty liver disease (NAFLD), a condition of increasing global prevalence and significant public health concern. The research provides a nuanced understanding of the disease's etiology by examining a cohort of 112 participants, including individuals with and without NAFLD. The study meticulously considers a spectrum of variables such as demographic factors, body composition metrics, and blood parameters. Advanced diagnostic tools like Fibroscan® are employed to ascertain NAFLD presence, ensuring accurate and reliable results.